文献速递核素与放射性配体治疗

多周期[177Lu]Lu-DOTATATE肽受体放射性核素治疗中的剂量学行为与剂量-效应关系

Multicycle Dosimetric Behavior and Dose-Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2025-06-02

研究转移性神经内分泌肿瘤患者接受标准[177Lu]Lu-DOTATATE肽受体放射性核素治疗后的药代动力学、剂量学模式及吸收剂量-效应相关性。肿瘤与肾脏吸收剂量比值随周期递减,肾吸收剂量与9个月时eGFR呈负相关,肿瘤吸收剂量与疗效指标无显著关联。

要点

  • 肿瘤与肾脏吸收剂量比值随周期递减,中位值第1-4周期分别为6.4、5.7、4.7、3.9。
  • 2级和胰腺神经内分泌肿瘤较低级别和肠道肿瘤每周期吸收剂量下降更显著且吸收剂量与有效半衰期更低。
  • 肾吸收剂量与9个月时eGFR呈显著负相关,调整基线eGFR后仍显著。

核心结论

  • 所报告的不同周期及不同神经内分泌肿瘤亚组的剂量学行为可用于优化个体化肽受体放射性核素治疗。
  • eGFR与吸收剂量关系的模型有潜力在治疗早期预测肾功能。
  • 报告的亚组药代动力学参数有助于在减少影像时间点的方案中选择更合适的人群参数。

研究设计与样本

  • 转移性神经内分泌肿瘤患者接受标准[177Lu]Lu-DOTATATE肽受体放射性核素治疗并连续行SPECT/CT显像。
  • 肾脏在CT上采用深度学习算法分割,肿瘤在每个周期采用SPECT梯度工具分割并以基线CT/MRI放射科医生勾画轮廓引导。
  • 剂量学采用自动化工作流程,包括基于轮廓强度的SPECT-SPECT配准、蒙特卡罗剂量率图生成和剂量率拟合。
  • 30例患者在第1周期后完成剂量学,其中22例完成所有周期SPECT/CT后行全周期剂量学。
  • 首次随访时采用实体瘤疗效评价标准(RECIST)、改良RECIST及[68Ga]Ga-DOTATATE PET标准评估病灶水平疗效,肾毒性基于治疗9个月后估算肾小球滤过率(eGFR)评估。

主要发现

  • 肿瘤(n=78)中位累积吸收剂量为2.2 Gy/GBq(范围0.1-20.8 Gy/GBq),肾脏中位吸收剂量为0.44 Gy/GBq(范围0.25-0.96 Gy/GBq)。
  • 肿瘤与肾脏吸收剂量比值随周期递减,第1-4周期中位值分别为6.4、5.7、4.7、3.9,因肿瘤吸收剂量下降而肾脏吸收剂量相对恒定。
  • 2级和胰腺神经内分泌肿瘤较低级别和肠道神经内分泌肿瘤每周期吸收剂量下降更显著,吸收剂量和有效半衰期也显著更低。
  • 低eGFR患者肾脏有效半衰期和吸收剂量显著高于高eGFR患者,肿瘤吸收剂量与疗效指标无显著关联。
  • 无高于2级的肾毒性;单变量分析中9个月时eGFR与肾脏吸收剂量呈显著负相关,多变量模型调整基线eGFR后仍显著(第1周期吸收剂量P=0.020,校正R²=0.57;累积吸收剂量P=0.049,校正R²=0.65),eGFR百分比变化与肾脏吸收剂量关联在调整基线eGFR后亦显著(第1周期吸收剂量P=0.006,校正R²=0.21;累积吸收剂量P=0.019,校正R²=0.21)。

临床怎么用

  • 作者认为所报告的不同周期和不同神经内分泌肿瘤亚组的剂量学行为可在优化个体化肽受体放射性核素治疗时予以考虑。
  • 作者认为其eGFR与吸收剂量关系的模型有潜力在治疗早期预测肾功能。
  • 作者认为报告的亚组药代动力学参数有助于在减少影像时间点的方案中选择更合适的人群参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated pharmacokinetics, dosimetric patterns, and absorbed dose (AD)-effect correlations in [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) for metastatic neuroendocrine tumors (NETs) to develop strategies for future personalized dosimetry-guided treatments. Methods: Patients treated with standard [177Lu]Lu-DOTATATE PRRT were recruited for serial SPECT/CT imaging. Kidneys were segmented on CT using a deep learning algorithm, and tumors were segmented at each cycle using a SPECT gradient-based tool, guided by radiologist-defined contours on baseline CT/MRI. Dosimetry was performed using an automated workflow that included contour intensity-based SPECT-SPECT registration, generation of Monte Carlo dose-rate maps, and dose-rate fitting. Lesion-level response at first follow-up was evaluated using both radiologic (RECIST and modified RECIST) and [68Ga]Ga-DOTATATE PET-based criteria. Kidney toxicity was evaluated based on the estimated glomerular filtration rate (eGFR) at 9 mo after PRRT. Results: Dosimetry was performed after cycle 1 in 30 patients and after all cycles in 22 of 30 patients who completed SPECT/CT imaging after each cycle. Median cumulative tumor (n = 78) AD was 2.2 Gy/GBq (range, 0.1-20.8 Gy/GBq), whereas median kidney AD was 0.44 Gy/GBq (range, 0.25-0.96 Gy/GBq). The tumor-to-kidney AD ratio decreased with each cycle (median, 6.4, 5.7, 4.7, and 3.9 for cycles 1-4) because of a decrease in tumor AD, while kidney AD remained relatively constant. Higher-grade (grade 2) and pancreatic NETs showed a significantly larger drop in AD with each cycle, as well as significantly lower AD and effective half-life (Teff), than did low-grade (grade 1) and small intestinal NETs, respectively. Teff remained relatively constant with each cycle for both tumors and kidneys. Kidney Teff and AD were significantly higher in patients with low eGFR than in those with high eGFR. Tumor AD was not significantly associated with response measures. There was no nephrotoxicity higher than grade 2; however, a significant negative association was found in univariate analyses between eGFR at 9 mo and AD to the kidney, which improved in a multivariable model that also adjusted for baseline eGFR (cycle 1 AD, P = 0.020, adjusted R 2 = 0.57; cumulative AD, P = 0.049, adjusted R 2 = 0.65). The association between percentage change in eGFR and AD to the kidney was also significant in univariate analysis and after adjusting for baseline eGFR (cycle 1 AD, P = 0.006, adjusted R 2 = 0.21; cumulative AD, P = 0.019, adjusted R 2 = 0.21). Conclusion: The dosimetric behavior we report over different cycles and for different NET subgroups can be considered when optimizing PRRT to individual patients. The models we present for the relationship between eGFR and AD have potential for clinical use in predicting renal function early in the treatment course. Furthermore, reported pharmacokinetics for patient subgroups allow more appropriate selection of population parameters to be used in protocols with fewer imaging time points that facilitate more widespread adoption of dosimetry.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kayal G, Roseland ME, Wang C, et al. Multicycle Dosimetric Behavior and Dose-Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2025. PMID: 40274371. doi:10.2967/jnumed.124.269389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。